Skip to main content

Table 5 Effect of the tested drugs on the Lactate dehydrogenase-1, Troponin I, and TNFα1 in alloxan-induced diabetic rats

From: Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

Myocardial biomarkers
Groups LDH-1 (IU/L) Troponin I (pg/ml) TNFα1 (pg/mL)
Normal control group 17.42 ± 0.69 92.12 ± 9.19 06.12 ± 0.45
Diabetic control group 18.50 ± 1.53 95.73 ± 8.23 08.32 ± 0.56
Diabetic group treated with bromocriptine 40.50 ± 10.69# 313.43 ± 29.43# 36.56 ± 2.32#
Diabetic group treated with cabergoline 36.86 ± 12.47# 143.23 ± 12.93# 31.20 ± 4.23#
Diabetic group treated with carpogrelate 19.55 ± 2.20 101.17 ± 8.45 09.74 ± 0.98
Diabetic group treated with bromocriptine + sarpogrelate 27.75 ± 3.91 a 241.34 ± 17.83a 14.84 ± 1.23 a
Diabetic group treated with cabergoline + sarpogrelate 34.57 ± 6.60 b 128.83 ± 13.53 08.59 ± 0.76 b
  1. Values shown are means ± SEM; n = 6 rats per group. # P < 0.05, significantly different from the diabetic control group. a P < 0.05, significantly different from the diabetic group treated with bromocriptine. b P < 0.05, significantly different from the diabetic group treated with cabergoline